RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting

BACKGROUND: RH5 is the leading vaccine candidate for the Plasmodium falciparum blood stage and has shown impact on parasite growth in the blood in a human clinical trial. RH5 binds to Ripr and CyRPA at the apical end of the invasive merozoite form, and this complex, designated RCR, is essential for...

Descripción completa

Detalles Bibliográficos
Autores principales: Healer, Julie, Thompson, Jennifer K., Mackwell, Karen L., Browne, Cecille D., Seager, Benjamin A., Ngo, Anna, Lowes, Kym N., Silk, Sarah E., Pulido, David, King, Lloyd D. W., Christen, Jayne M., Noe, Amy R., Kotraiah, Vinayaka, Masendycz, Paul J., Rajagopalan, Rajkannan, Lucas, Leanne, Stanford, Marianne M., Soisson, Lorraine, Diggs, Carter, Miller, Robin, Youll, Susan, Wycherley, Kaye, Draper, Simon J., Cowman, Alan F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807911/
https://www.ncbi.nlm.nih.gov/pubmed/36605129
http://dx.doi.org/10.3389/fcimb.2022.1049065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807911/
https://www.ncbi.nlm.nih.gov/pubmed/36605129
http://dx.doi.org/10.3389/fcimb.2022.1049065

Ejemplares similares